ARDX

A class action lawsuit has been filed against Ardelyx, Inc. alleging that the company made false and misleading statements regarding its commercial performance. The complaint claims Ardelyx failed to disclose increasing payer-related access barriers, stringent prior authorization requirements, and negative impacts on growth prospects for its drugs XPHOZAH and IBSRELA during the period from January 13, 2025 to August 6, 2026.

Rosen Law Firm is reminding investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 of an important November 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues affecting its drugs XPHOZAH and IBSRELA.

A securities class action has been filed against Ardelyx, Inc. (NASDAQ: ARDX) alleging the company misled investors about its commercial performance and growth prospects for its drug products IBSRELA and XPHOZAH. The lawsuit covers purchases between January 13, 2025 and August 6, 2026. On August 6, 2026, Ardelyx reduced its full-year 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance due to increased payer access barriers, causing the stock to drop 18% in one day from $4.87 to $4.00 per share.

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Ardelyx, Inc. for alleged securities violations. The lawsuit claims the company made false and misleading statements regarding reimbursement barriers and patient access issues for its drugs XPHOZAH and IBSRELA, which impacted commercial performance. The class period spans January 13, 2025 to August 6, 2026, with a deadline of November 16, 2026 for shareholders to participate.

A class action lawsuit has been filed against Ardelyx, Inc. for alleged securities fraud. The complaint alleges that the company made false and misleading statements regarding payer access barriers, prior authorization requirements, and commercial performance of its drugs XPHOZAH and IBSRELA during the period from January 13, 2025 to August 6, 2026. Investors have until November 16, 2026 to request lead plaintiff status.

Rosen Law Firm is urging investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 to join a securities class action lawsuit. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA, resulting in investor damages.

Rosen Law Firm is reminding investors in Anavex Life Sciences, Ardelyx, and AST SpaceMobile to join securities class action lawsuits before upcoming deadlines. The lawsuits allege that these companies made false or misleading statements regarding their business operations, internal controls, and regulatory challenges. Investors who purchased securities during specified class periods may be entitled to compensation.

Rosen Law Firm is soliciting investors who purchased securities of Ardelyx, Inc., Anavex Life Sciences Corp., and AST SpaceMobile, Inc. during specified periods to join class action lawsuits. The firm alleges these companies made materially false statements regarding commercial performance and growth prospects. Investors have until November 16, 2026 to serve as lead plaintiffs.

Zacks has added three stocks to its Strong Sell list: Accendra Health (ACH), Ardelyx (ARDX), and Draganfly (DPRO). All three companies have experienced significant downward revisions to their earnings estimates over the past 60 days, with ACH seeing a 109.4% downward revision, ARDX a 25% revision, and DPRO a 59.6% revision.

Rosen Law Firm is urging investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 to join a securities class action lawsuit. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA, resulting in investor damages.

Rosen Law Firm has filed securities class action lawsuits against Hims & Hers Health, Duolingo, and Ardelyx. The Hims lawsuit alleges the company made false statements regarding data privacy practices, prescription charging procedures, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased securities during specified class periods are encouraged to join the litigation before the November 2, 2026 lead plaintiff deadline.

Zacks has added three stocks to its Strong Sell list today: Ardelyx (ARDX), a biopharmaceutical company with a 53.9% downward earnings revision; Southwest Airlines (LUV), a passenger airline with a 4.1% downward earnings revision; and Collegium Pharmaceutical (COLL), a specialty pharmaceutical company with a nearly 3% downward earnings revision over the last 60 days.

Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against Baidu, Ardelyx, and Better Home & Finance Holding Company. The lawsuits allege materially false and misleading statements regarding business operations and financial projections. Investors who purchased shares during specified periods and suffered losses are encouraged to seek legal representation.

Rosen Law Firm is notifying investors in Ardelyx, Inc. who purchased stock between January 13, 2025 and August 6, 2026 about a securities class action lawsuit. The complaint alleges that Ardelyx made materially false and misleading statements regarding commercial performance and growth prospects for its drugs XPHOZAH and IBSRELA, while concealing information about payer access barriers, prior authorization requirements, and step edit requirements that hindered patient access. Investors have until November 16, 2026 to serve as lead plaintiff.

A class action lawsuit has been filed against Ardelyx, Inc. alleging that the company made false and misleading statements regarding payer access barriers and reimbursement issues affecting its drugs XPHOZAH and IBSRELA. The lawsuit covers investors who purchased Ardelyx securities between January 13, 2025 and August 6, 2026. The lead plaintiff deadline is November 16, 2026.

Rosen Law Firm is reminding investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 of an important November 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA.

Pomerantz Law Firm has filed class action lawsuits against XTI Aerospace, Baidu, and Ardelyx for alleged securities fraud and unlawful business practices. XTI Aerospace experienced a significant stock price decline of 15.92% following disclosure of an internal review of its former CEO who resigned on August 17, 2026. Investors have until October 27, 2026, to request Lead Plaintiff status.

Rosen Law Firm has filed a class action lawsuit on behalf of Ardelyx, Inc. (NASDAQ: ARDX) investors who purchased stock between January 13, 2025 and August 6, 2026. The lawsuit alleges that defendants made materially false and misleading statements about the company's commercial performance and growth prospects for drugs XPHOZAH and IBSRELA, while concealing information about payer-related access barriers, prior authorization requirements, and step edit requirements that hindered patient access and new-patient starts. The deadline to serve as lead plaintiff is November 16, 2026.

Robbins LLP reminds investors of the November 16, 2026 lead plaintiff deadline in a securities class action against Ardelyx, Inc. (ARDX). The lawsuit alleges the company misled investors about commercial performance and growth prospects for its drugs ISBRELA and XPHOZAH, concealing material adverse facts about payer access barriers and reimbursement challenges. On August 6, 2026, Ardelyx reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance, causing the stock to drop 18% in one day from $4.87 to $4.00 per share.

Schall, Brown & Schwartz LLP has filed a class action lawsuit against Ardelyx, Inc. for alleged securities violations under the Securities Exchange Act of 1934. The lawsuit claims the company made false and misleading statements regarding reimbursement barriers that impacted patient access to its drugs XPHOZAH and IBSRELA, causing delays in new-patient starts and prescription fulfillment. The class period runs from January 13, 2025 to August 6, 2026, with a deadline of November 16, 2026 for shareholders to participate.